ID	Gene Name	Species	BIOCARTA	GOTERM_BP_DIRECT	GOTERM_CC_DIRECT	GOTERM_MF_DIRECT	INTERPRO	KEGG_PATHWAY	OMIM_DISEASE	PIR_SUPERFAMILY	SMART	UP_KW_BIOLOGICAL_PROCESS	UP_KW_CELLULAR_COMPONENT	UP_KW_DISEASE	UP_KW_DOMAIN	UP_KW_LIGAND	UP_KW_MOLECULAR_FUNCTION	UP_KW_PTM	UP_SEQ_FEATURE
9429	ATP binding cassette subfamily G member 2 (Junior blood group)(ABCG2)	Homo sapiens		GO:0006869~lipid transport,GO:0015711~organic anion transport,GO:0015747~urate transport,GO:0015878~biotin transport,GO:0032218~riboflavin transport,GO:0046415~urate metabolic process,GO:0055085~transmembrane transport,GO:0070633~transepithelial transport,GO:0097744~urate salt excretion,GO:1990748~cellular detoxification,GO:1990962~drug transport across blood-brain barrier,	GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0031526~brush border membrane,GO:0031966~mitochondrial membrane,GO:0045121~membrane raft,GO:0098591~external side of apical plasma membrane,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008514~organic anion transmembrane transporter activity,GO:0008559~xenobiotic-transporting ATPase activity,GO:0015143~urate transmembrane transporter activity,GO:0015225~biotin transporter activity,GO:0015562~efflux transmembrane transporter activity,GO:0032217~riboflavin transporter activity,GO:0042626~ATPase activity, coupled to transmembrane movement of substances,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0042910~xenobiotic transporter activity,	IPR003439:ABC transporter-like,IPR003593:AAA+ ATPase domain,IPR013525:ABC-2 type transporter,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa01523:Antifolate resistance,hsa02010:ABC transporters,hsa04976:Bile secretion,	138900~Uric acid concentration, serum, QTL1,614490~Junior blood group system,		SM00382:AAA,	KW-0445~Lipid transport,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-1278~Translocase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	BINDING:ATP,CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,DOMAIN:ABC transmembrane type-2,DOMAIN:ABC transporter,DOMAIN:ABC2_membrane_7,MUTAGEN:C->A: Strongly reduced binding to hemin but not to PPIX.,MUTAGEN:E->Q: Decreased estrone-3 sulfate ATPase-coupled transmembrane transporter activity. Decreased substrate-induced ATP hydrolysis. Decreased substrate transport.,MUTAGEN:F->A: No effect on stability. Decreased estrone-3 sulfate ATPase-coupled transmembrane transporter activity. Decreased substrate-induced ATP hydrolysis. Decreased substrate transport.,MUTAGEN:H->A: Strongly reduced binding to hemin but not to PPIX.,MUTAGEN:K->M: Decreased protein abundance. Decreased localization to the plasma membrane and retained intracellularly. Loss of ATPase-coupled transmembrane transporter activity.,MUTAGEN:L->A: Loss of protein expression.,MUTAGEN:L->A: No effect on stability. Increased estrone-3 sulfate ATPase-coupled transmembrane transporter activity. Increased basal and substrate-induced ATP hydrolysis. Increased substrate transport.,MUTAGEN:M->A: No effect on stability. No effect on estrone-3 sulfate ATPase-coupled transmembrane transporter activity. No effect on substrate-induced ATP hydrolysis. No effect on substrate transport.,MUTAGEN:M->V: Decreased protein abundance. No effect on substrate transmembrane transport.,MUTAGEN:N->A: No effect on stability. Decreased estrone-3 sulfate ATPase-coupled transmembrane transporter activity. Decreased substrate-induced ATP hydrolysis. Decreased substrate transport.,MUTAGEN:N->Q: Loss of glycosylation.,MUTAGEN:N->Q: No effect.,MUTAGEN:R->C: Loss of protein expression.,MUTAGEN:R->D: Decreases ATPase activity.,MUTAGEN:R->G,N,S,T: Increases ATPase activity.,MUTAGEN:R->K,I,M,Y: No change in ATPase activity.,MUTAGEN:R->T,Y: Decreases transport activity.,MUTAGEN:T->A: Loss of phosphorylation by PIM1. Decreased localization to the plasma membrane. Decreased homooligomerization. Loss of function in resistance to drug treatment.,MUTAGEN:T->A: No effect on stability. Increased estrone-3 sulfate ATPase-coupled transmembrane transporter activity. Increased substrate-induced ATP hydrolysis. Increased substrate transport.,MUTAGEN:T->D: Loss of phosphorylation by PIM1. Constitutive drug resistance independent of PIM1.,MUTAGEN:T->F: No effect on stability. Decreased estrone-3 sulfate ATPase-coupled transmembrane transporter activity. Decreased substrate-induced ATP hydrolysis. Decreased substrate transport.,MUTAGEN:V->A: No effect on stability. No effect on estrone-3 sulfate ATPase-coupled transmembrane transporter activity. No effect on substrate-induced ATP hydrolysis. No effect on substrate transport.,MUTAGEN:V->F: No effect on stability. Decreased estrone-3 sulfate ATPase-coupled transmembrane transporter activity. Increased basal and substrate-induced ATP hydrolysis. Decreased substrate transport.,MUTAGEN:Y->A: No effect on hemin binding.,NP_BIND:ATP,SITE:Not glycosylated,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
79923	Nanog homeobox(NANOG)	Homo sapiens		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001714~endodermal cell fate specification,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0010468~regulation of gene expression,GO:0019827~stem cell population maintenance,GO:0030154~cell differentiation,GO:0035019~somatic stem cell population maintenance,GO:0045595~regulation of cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:2000648~positive regulation of stem cell proliferation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0043231~intracellular membrane-bounded organelle,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,	hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa05205:Proteoglycans in cancer,			SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,KW-0677~Repeat,		KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,MUTAGEN:F->A: No effect on POU5F1 promoter DNA-binding.,MUTAGEN:K->A: Decreased POU5F1 promoter DNA-binding and protein stability.,MUTAGEN:K->A: Inhibits POU5F1 promoter DNA-binding.,MUTAGEN:L->A: Increased POU5F1 promoter DNA-binding and protein stability.,MUTAGEN:M->A: Decreased POU5F1 promoter DNA-binding and protein stability.,MUTAGEN:M->A: No effect on POU5F1 promoter DNA-binding. Increased protein stability.,MUTAGEN:N->A: Inhibits POU5F1 promoter DNA-binding.,MUTAGEN:Q->A: Decreased POU5F1 promoter DNA-binding and protein stability.,MUTAGEN:Q->A: No effect on POU5F1 promoter DNA-binding. Decreased protein stability.,MUTAGEN:R->A: Inhibits POU5F1 promoter DNA-binding.,MUTAGEN:T->A: Inhibits POU5F1 promoter DNA-binding.,MUTAGEN:Y->A: Decreased POU5F1 promoter DNA-binding and protein stability.,REGION:8 X repeats starting with a Trp in each unit,REGION:Disordered,REGION:Required for DNA-binding,REGION:Sufficient for strong transactivation activity,REGION:Sufficient for transactivation activity,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,
6657	SRY-box transcription factor 2(SOX2)	Homo sapiens		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001649~osteoblast differentiation,GO:0001654~eye development,GO:0001714~endodermal cell fate specification,GO:0006325~chromatin organization,GO:0006355~regulation of transcription, DNA-templated,GO:0009611~response to wounding,GO:0009653~anatomical structure morphogenesis,GO:0010468~regulation of gene expression,GO:0021781~glial cell fate commitment,GO:0021983~pituitary gland development,GO:0021984~adenohypophysis development,GO:0022409~positive regulation of cell-cell adhesion,GO:0030154~cell differentiation,GO:0030900~forebrain development,GO:0035019~somatic stem cell population maintenance,GO:0042246~tissue regeneration,GO:0043281~regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043410~positive regulation of MAPK cascade,GO:0045165~cell fate commitment,GO:0045597~positive regulation of cell differentiation,GO:0045665~negative regulation of neuron differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048839~inner ear development,GO:0050680~negative regulation of epithelial cell proliferation,GO:0051726~regulation of cell cycle,GO:0070848~response to growth factor,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0097150~neuronal stem cell population maintenance,GO:1902807~negative regulation of cell cycle G1/S phase transition,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016607~nuclear speck,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0035198~miRNA binding,GO:0043565~sequence-specific DNA binding,	IPR009071:High mobility group (HMG) box domain,IPR022097:Transcription factor SOX,	hsa04390:Hippo signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,	206900~Microphthalmia, syndromic 3,206900~Optic nerve hypoplasia and abnormalities of the central nervous system,		SM00398:HMG,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1013~Microphthalmia,			KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DNA_BIND:HMG box,DOMAIN:HMG box,MOTIF:9aaTAD,MUTAGEN:KR->AA: In mt1; reduced nuclear import; when associated with 56-A--A-58. In mt1.2; reduced nuclear import; when associated with 56-A--A-58 and 113-A--A-115.,MUTAGEN:RRK->AAA: In mt1; reduced nuclear import; when associated with 56-A--A-58. In mt1.2; reduced nuclear import; when associated with 42-A-A-43 and 113-A--A-115.,MUTAGEN:RRK->AAA: In mt2; reduced nuclear import. In mt1.2; reduced nuclear import; when associated with 42-A-A-43 and 56-A--A-58.,REGION:Disordered,
217	aldehyde dehydrogenase 2 family member(ALDH2)	Homo sapiens		GO:0005975~carbohydrate metabolic process,GO:0006066~alcohol metabolic process,GO:0006068~ethanol catabolic process,GO:0022900~electron transport chain,GO:0046185~aldehyde catabolic process,GO:1903179~regulation of dopamine biosynthetic process,GO:1905627~regulation of serotonin biosynthetic process,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0070062~extracellular exosome,	GO:0004029~aldehyde dehydrogenase (NAD) activity,GO:0004030~aldehyde dehydrogenase [NAD(P)+] activity,GO:0008957~phenylacetaldehyde dehydrogenase activity,GO:0009055~electron carrier activity,GO:0016620~oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor,GO:0018547~nitroglycerin reductase activity,GO:0043878~glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity,GO:0051287~NAD binding,GO:0052689~carboxylic ester hydrolase activity,	IPR015590:Aldehyde dehydrogenase domain,IPR016160:Aldehyde dehydrogenase, conserved site,IPR016161:Aldehyde/histidinol dehydrogenase,IPR016162:Aldehyde dehydrogenase, N-terminal,IPR016163:Aldehyde dehydrogenase, C-terminal,	hsa00010:Glycolysis / Gluconeogenesis,hsa00053:Ascorbate and aldarate metabolism,hsa00071:Fatty acid degradation,hsa00280:Valine, leucine and isoleucine degradation,hsa00310:Lysine degradation,hsa00330:Arginine and proline metabolism,hsa00340:Histidine metabolism,hsa00380:Tryptophan metabolism,hsa00410:beta-Alanine metabolism,hsa00561:Glycerolipid metabolism,hsa00620:Pyruvate metabolism,hsa00770:Pantothenate and CoA biosynthesis,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,hsa04936:Alcoholic liver disease,	610251~Alcohol sensitivity, acute,610251~Hangover, susceptibility to,Esophageal cancer, alcohol-related, susceptibility to~Esophageal cancer, alcohol-related, susceptibility to,Sublingual nitroglycerin, susceptibility to poor response to~Sublingual nitroglycerin, susceptibility to poor response to,				KW-0496~Mitochondrion,		KW-0809~Transit peptide,	KW-0520~NAD,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,	ACT_SITE:Nucleophile,ACT_SITE:Proton acceptor,DOMAIN:Aldedh,NP_BIND:NAD,SITE:Transition state stabilizer,TRANSIT:Mitochondrion,
151871	developmental pluripotency associated 2(DPPA2)	Homo sapiens		GO:0048731~system development,	GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0003682~chromatin binding,GO:0005515~protein binding,	IPR003034:SAP domain,IPR025891:Developmental pluripotency-associated protein 2/4, C-terminal domain,IPR025892:Developmental pluripotency-associated protein 2/4, central domain,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,						DOMAIN:SAP,REGION:Disordered,
1956	epidermal growth factor receptor(EGFR)	Homo sapiens	h_agrPathway:Agrin in Postsynaptic Differentiation,h_at1rPathway:Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling,h_cardiacEGFPathway:Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy,h_cblPathway:CBL mediated ligand-induced downregulation of EGF receptors,h_eea1Pathway:The role of FYVE-finger proteins in vesicle transport,h_egfPathway:EGF Signaling Pathway,h_egfr_smrtePathway:Map Kinase Inactivation of SMRT Corepressor,h_ErbB3Pathway:Neuroregulin receptor degredation protein-1 Controls ErbB3 receptor recycling,h_erkPathway:Erk1/Erk2 Mapk Signaling pathway,h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,h_keratinocytePathway:Keratinocyte Differentiation,h_mCalpainPathway:mCalpain and friends in Cell motility,h_spryPathway:Sprouty regulation of tyrosine kinase signals,h_telPathway:Telomeres, Telomerase, Cellular Aging, and  Immortality,h_tffPathway:Trefoil Factors Initiate  Mucosal Healing,	GO:0000165~MAPK cascade,GO:0000902~cell morphogenesis,GO:0001503~ossification,GO:0001892~embryonic placenta development,GO:0001934~positive regulation of protein phosphorylation,GO:0001942~hair follicle development,GO:0006412~translation,GO:0006898~receptor-mediated endocytosis,GO:0006970~response to osmotic stress,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007171~activation of transmembrane receptor protein tyrosine kinase activity,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007202~activation of phospholipase C activity,GO:0007275~multicellular organism development,GO:0007435~salivary gland morphogenesis,GO:0007494~midgut development,GO:0007611~learning or memory,GO:0007623~circadian rhythm,GO:0008284~positive regulation of cell proliferation,GO:0010750~positive regulation of nitric oxide mediated signal transduction,GO:0010960~magnesium ion homeostasis,GO:0014066~regulation of phosphatidylinositol 3-kinase signaling,GO:0016101~diterpenoid metabolic process,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0021795~cerebral cortex cell migration,GO:0030154~cell differentiation,GO:0030307~positive regulation of cell growth,GO:0030324~lung development,GO:0030335~positive regulation of cell migration,GO:0032930~positive regulation of superoxide anion generation,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0033590~response to cobalamin,GO:0033594~response to hydroxyisoflavone,GO:0033674~positive regulation of kinase activity,GO:0034614~cellular response to reactive oxygen species,GO:0035690~cellular response to drug,GO:0038083~peptidyl-tyrosine autophosphorylation,GO:0038134~ERBB2-EGFR signaling pathway,GO:0042059~negative regulation of epidermal growth factor receptor signaling pathway,GO:0042060~wound healing,GO:0042177~negative regulation of protein catabolic process,GO:0042311~vasodilation,GO:0042327~positive regulation of phosphorylation,GO:0042698~ovulation cycle,GO:0042743~hydrogen peroxide metabolic process,GO:0043006~activation of phospholipase A2 activity by calcium-mediated signaling,GO:0043066~negative regulation of apoptotic process,GO:0043406~positive regulation of MAP kinase activity,GO:0043586~tongue development,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045739~positive regulation of DNA repair,GO:0045740~positive regulation of DNA replication,GO:0045780~positive regulation of bone resorption,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045907~positive regulation of vasoconstriction,GO:0045930~negative regulation of mitotic cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046328~regulation of JNK cascade,GO:0046718~viral entry into host cell,GO:0046777~protein autophosphorylation,GO:0048143~astrocyte activation,GO:0048146~positive regulation of fibroblast proliferation,GO:0048546~digestive tract morphogenesis,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0048812~neuron projection morphogenesis,GO:0050673~epithelial cell proliferation,GO:0050679~positive regulation of epithelial cell proliferation,GO:0050729~positive regulation of inflammatory response,GO:0050730~regulation of peptidyl-tyrosine phosphorylation,GO:0050999~regulation of nitric-oxide synthase activity,GO:0051205~protein insertion into membrane,GO:0051592~response to calcium ion,GO:0051897~positive regulation of protein kinase B signaling,GO:0051968~positive regulation of synaptic transmission, glutamatergic,GO:0060252~positive regulation of glial cell proliferation,GO:0060571~morphogenesis of an epithelial fold,GO:0061029~eyelid development in camera-type eye,GO:0061098~positive regulation of protein tyrosine kinase activity,GO:0070141~response to UV-A,GO:0070257~positive regulation of mucus secretion,GO:0070372~regulation of ERK1 and ERK2 cascade,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071230~cellular response to amino acid stimulus,GO:0071260~cellular response to mechanical stimulus,GO:0071276~cellular response to cadmium ion,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071392~cellular response to estradiol stimulus,GO:0071549~cellular response to dexamethasone stimulus,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0097421~liver regeneration,GO:0098609~cell-cell adhesion,GO:1900020~positive regulation of protein kinase C activity,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1902722~positive regulation of prolactin secretion,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1903800~positive regulation of production of miRNAs involved in gene silencing by miRNA,GO:1905208~negative regulation of cardiocyte differentiation,	GO:0000139~Golgi membrane,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0009925~basal plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0030054~cell junction,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0031965~nuclear membrane,GO:0032587~ruffle membrane,GO:0032991~macromolecular complex,GO:0043235~receptor complex,GO:0044214~spanning component of plasma membrane,GO:0045121~membrane raft,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,GO:0070435~Shc-EGFR complex,GO:0097489~multivesicular body, internal vesicle lumen,GO:0097708~intracellular vesicle,	GO:0001618~virus receptor activity,GO:0003682~chromatin binding,GO:0003690~double-stranded DNA binding,GO:0004672~protein kinase activity,GO:0004709~MAP kinase kinase kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004888~transmembrane signaling receptor activity,GO:0005006~epidermal growth factor-activated receptor activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0019899~enzyme binding,GO:0019900~kinase binding,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0030235~nitric-oxide synthase regulator activity,GO:0030296~protein tyrosine kinase activator activity,GO:0030297~transmembrane receptor protein tyrosine kinase activator activity,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,GO:0045296~cadherin binding,GO:0048408~epidermal growth factor binding,GO:0051015~actin filament binding,GO:0051117~ATPase binding,	IPR000494:EGF receptor, L domain,IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR006211:Furin-like cysteine-rich domain,IPR006212:Furin-like repeat,IPR008266:Tyrosine-protein kinase, active site,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011009:Protein kinase-like domain,IPR016245:Tyrosine protein kinase, EGF/ERB/XmrK receptor,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04144:Endocytosis,hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04540:Gap junction,hsa04630:JAK-STAT signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa04912:GnRH signaling pathway,hsa04915:Estrogen signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04926:Relaxin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04934:Cushing syndrome,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05131:Shigellosis,hsa05160:Hepatitis C,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05219:Bladder cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05230:Central carbon metabolism in cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,	211980~Adenocarcinoma of lung, response to tyrosine kinase inhibitor in,211980~Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in,211980~Nonsmall cell lung cancer, susceptibility to,616069~Inflammatory skin and bowel disease, neonatal, 2,	PIRSF000619:tyrosine-protein kinase, EGF receptor type,	SM00219:TyrKc,SM00261:FU,	KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0964~Secreted,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0217~Developmental protein,KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,KW-1183~Host cell receptor for virus entry,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,CARBOHYD:N-linked (GlcNAc...) (complex) asparagine; atypical; partial,CARBOHYD:N-linked (GlcNAc...) (high mannose) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine; atypical,CARBOHYD:N-linked (GlcNAc...) asparagine; partial,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Furin-like,DOMAIN:GF_recep_IV,DOMAIN:PK_Tyr_Ser-Thr,DOMAIN:Protein kinase,DOMAIN:Recep_L_domain,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Decreased palmitoylation.,MUTAGEN:D->A: Increased EGF binding; when associated with A-590 and A-609.,MUTAGEN:D->A: Strongly reduced phosphorylation.,MUTAGEN:DGPH->AGPA: Decreases intramolecular interactions and facilitates EGF binding.,MUTAGEN:E->A: Reduced phosphorylation.,MUTAGEN:ED->RK: Constitutively activated kinase.,MUTAGEN:F->A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-309.,MUTAGEN:H->A: Increased EGF binding; when associated with A-587; A-590 and A-609.,MUTAGEN:I->A: Abolishes phosphorylation.,MUTAGEN:K->A,M: Abolishes kinase activity.,MUTAGEN:K->A: Decreases intramolecular interactions and facilitates EGF binding. Increased EGF binding; when associated with A-587; A-590 and A-609.,MUTAGEN:L->A,P: Strongly reduced phosphorylation.,MUTAGEN:L->A: Abolishes phosphorylation.,MUTAGEN:L->A: Strongly reduced phosphorylation.,MUTAGEN:Missing: Abolishes palmitoylation.,MUTAGEN:Missing: Increased EGF binding.,MUTAGEN:N->A: Abolishes phosphorylation.,MUTAGEN:P->A: Reduced phosphorylation.,MUTAGEN:P->A: Strongly reduced phosphorylation.,MUTAGEN:Q->G: No effect on interaction with CBLC.,MUTAGEN:R->A: Abolishes phosphorylation.,MUTAGEN:R->A: Reduced phosphorylation.,MUTAGEN:R->E: Abolishes autophosphorylation and activation of downstream kinases.,MUTAGEN:R->G: Strongly decreases interaction with CBLC.,MUTAGEN:R->S: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-275. Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-287.,MUTAGEN:T->A: Increased phosphorylation.,MUTAGEN:T->D: Strongly reduced phosphorylation.,MUTAGEN:V->A: Reduced autophosphorylation.,MUTAGEN:V->M: Constitutively activated kinase.,MUTAGEN:Y->A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-309.,MUTAGEN:Y->F: 50% decrease in interaction with PIK3C2B. 65% decrease in interaction with PIK3C2B; when associated with F-1197. Abolishes interaction with PIK3C2B; when associated with F-1197 and F-1092.,MUTAGEN:Y->F: Abolishes interaction with CBLC.,MUTAGEN:Y->F: No change in interaction with PIK3C2B.,MUTAGEN:Y->F: No change in interaction with PIK3C2B. 65% decrease in interaction with PIK3C2B; when associated with F-1016. Abolishes interaction with PIK3C2B; when associated with F-1092 and F-1016.,MUTAGEN:Y->F: No change in interaction with PIK3C2B. Abolishes interaction with PIK3C2B; when associated with F-1197 and F-1016.,NP_BIND:ATP,REGION:Disordered,REGION:Important for dimerization, phosphorylation and activation,REPEAT:Approximate,SITE:Important for interaction with PIK3C2B,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
2065	erb-b2 receptor tyrosine kinase 3(ERBB3)	Homo sapiens	h_ErbB3Pathway:Neuroregulin receptor degredation protein-1 Controls ErbB3 receptor recycling,h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology,	GO:0003197~endocardial cushion development,GO:0006468~protein phosphorylation,GO:0007162~negative regulation of cell adhesion,GO:0007165~signal transduction,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007275~multicellular organism development,GO:0007399~nervous system development,GO:0007422~peripheral nervous system development,GO:0007507~heart development,GO:0008284~positive regulation of cell proliferation,GO:0009968~negative regulation of signal transduction,GO:0010628~positive regulation of gene expression,GO:0014037~Schwann cell differentiation,GO:0014065~phosphatidylinositol 3-kinase signaling,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0021545~cranial nerve development,GO:0033674~positive regulation of kinase activity,GO:0038133~ERBB2-ERBB3 signaling pathway,GO:0042060~wound healing,GO:0042127~regulation of cell proliferation,GO:0043524~negative regulation of neuron apoptotic process,GO:0051048~negative regulation of secretion,GO:0051402~neuron apoptotic process,GO:0055025~positive regulation of cardiac muscle tissue development,GO:0061098~positive regulation of protein tyrosine kinase activity,GO:0070886~positive regulation of calcineurin-NFAT signaling cascade,GO:0097049~motor neuron apoptotic process,GO:0097192~extrinsic apoptotic signaling pathway in absence of ligand,GO:2000672~negative regulation of motor neuron apoptotic process,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009925~basal plasma membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0016328~lateral plasma membrane,GO:0038143~ERBB3:ERBB2 complex,GO:0043235~receptor complex,GO:0044214~spanning component of plasma membrane,	GO:0004672~protein kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019838~growth factor binding,GO:0030296~protein tyrosine kinase activator activity,GO:0031625~ubiquitin protein ligase binding,GO:0038131~neuregulin receptor activity,GO:0038132~neuregulin binding,GO:0042802~identical protein binding,GO:0043125~ErbB-3 class receptor binding,GO:0046982~protein heterodimerization activity,	IPR000494:EGF receptor, L domain,IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR006211:Furin-like cysteine-rich domain,IPR006212:Furin-like repeat,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011009:Protein kinase-like domain,IPR016245:Tyrosine protein kinase, EGF/ERB/XmrK receptor,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04020:Calcium signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,	133180~Erythroleukemia, familial, susceptibility to,243180~Visceral neuropathy, familial, 1, autosomal recessive,607598~Lethal congenital contractural syndrome 2,	PIRSF000619:tyrosine-protein kinase, EGF receptor type,	SM00219:TyrKc,SM00261:FU,		KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,BINDING:ATP,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:GF_recep_IV,DOMAIN:PK_Tyr_Ser-Thr,DOMAIN:Protein kinase,DOMAIN:Recep_L_domain,DOMAIN:TyrKc,MUTAGEN:K->M: Strongly reduced autophosphorylation.,MUTAGEN:Y->E: Strongly reduced tyrosine phosphorylation.,NP_BIND:ATP,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
3151	high mobility group nucleosomal binding domain 2(HMGN2)	Homo sapiens		GO:0006325~chromatin organization,GO:0031640~killing of cells of other organism,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,	GO:0000785~chromatin,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0031492~nucleosomal DNA binding,	IPR000079:High mobility group nucleosome-binding domain-containing family,				SM00527:HMG17,		KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,REGION:Disordered,
100506658	occludin(OCLN)	Homo sapiens		GO:0001933~negative regulation of protein phosphorylation,GO:0010592~positive regulation of lamellipodium assembly,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010827~regulation of glucose transport,GO:0031116~positive regulation of microtubule polymerization,GO:0035633~maintenance of permeability of blood-brain barrier,GO:0045216~cell-cell junction organization,GO:0046326~positive regulation of glucose import,GO:0065003~macromolecular complex assembly,GO:0070673~response to interleukin-18,GO:0070830~bicellular tight junction assembly,GO:0071356~cellular response to tumor necrosis factor,GO:0090303~positive regulation of wound healing,GO:1902463~protein localization to cell leading edge,GO:1905605~positive regulation of maintenance of permeability of blood-brain barrier,	GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0005923~bicellular tight junction,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0016327~apicolateral plasma membrane,GO:0016328~lateral plasma membrane,GO:0030054~cell junction,GO:0030139~endocytic vesicle,GO:0031252~cell leading edge,GO:0031410~cytoplasmic vesicle,GO:0032991~macromolecular complex,GO:0070160~occluding junction,	GO:0005515~protein binding,GO:0019904~protein domain specific binding,	IPR002958:Occludin,IPR008253:Marvel,IPR010844:Occludin/RNA polymerase II elongation factor, ELL domain,	hsa04514:Cell adhesion molecules,hsa04530:Tight junction,hsa04670:Leukocyte transendothelial migration,hsa05130:Pathogenic Escherichia coli infection,hsa05160:Hepatitis C,	251290~Pseudo-TORCH syndrome 1,	PIRSF005993:occludin,			KW-0472~Membrane,KW-0796~Tight junction,KW-0965~Cell junction,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,DOMAIN:MARVEL,DOMAIN:OCEL,MUTAGEN:T->A: Loss of localization to the tight junctions.,MUTAGEN:Y->A: Loss of phosphorylation and loss of regulation of TJP1 binding; when associated with A-398.,MUTAGEN:Y->A: Loss of phosphorylation and loss of regulation of TJP1 binding; when associated with A-402.,MUTAGEN:Y->D: Loss of phosphorylation, almost complete loss of binding to TJP1, loss of regulation of TJP1 binding and loss of localization to plasma membrane and sites of cell-cell contact; when associated with D-398.,MUTAGEN:Y->D: Loss of phosphorylation, almost complete loss of binding to TJP1, loss of regulation of TJP1 binding and loss of localization to plasma membrane and sites of cell-cell contact; when associated with D-402.,MUTAGEN:Y->F: Loss of phosphorylation, decrease in binding to TJP1 and significant loss of regulation of TJP1 binding; when associated with F-398.,MUTAGEN:Y->F: Loss of phosphorylation, decrease in binding to TJP1 and significant loss of regulation of TJP1 binding; when associated with F-402.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
9839	zinc finger E-box binding homeobox 2(ZEB2)	Homo sapiens		GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007399~nervous system development,GO:0030511~positive regulation of transforming growth factor beta receptor signaling pathway,GO:0045636~positive regulation of melanocyte differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048023~positive regulation of melanin biosynthetic process,GO:0048066~developmental pigmentation,GO:0048856~anatomical structure development,GO:0050790~regulation of catalytic activity,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0097324~melanocyte migration,GO:1903056~regulation of melanosome organization,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0019208~phosphatase regulator activity,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,	IPR001356:Homeodomain,IPR008598:Drought induced 19/ RING finger protein 114,IPR009057:Homeodomain-like,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,	hsa05206:MicroRNAs in cancer,	235730~Mowat-Wilson syndrome,		SM00355:ZnF_C2H2,SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0158~Chromosome,KW-0539~Nucleus,	KW-0225~Disease variant,KW-0367~Hirschsprung disease,KW-0887~Epilepsy,KW-0991~Mental retardation,	KW-0371~Homeobox,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DNA_BIND:Homeobox; atypical,DOMAIN:C2H2-type,REGION:Disordered,REGION:SMAD-MH2 binding domain,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4; atypical,ZN_FING:C2H2-type 5; atypical,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8; atypical,